1
|
Vultaggio A, Nencini F, Bormioli S, Silvestri E, Dies L, Vivarelli E, Maggi E, Matucci A. Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis. Sci Rep 2021; 11:12558. [PMID: 34131173 PMCID: PMC8206099 DOI: 10.1038/s41598-021-91851-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Accepted: 06/01/2021] [Indexed: 11/19/2022] Open
Abstract
Biologic agents (BA) are able to induce an adaptive immune response in a proportion of exposed patients with the onset of anti-drug antibodies (ADA), which are usually responsible for hypersensitivity reactions (HR). Drug desensitization (DD) for BA allows transient clinical tolerance to the drug in reactive patients. The paper aimed to analyse the modification of drug-specific immune responses along DD in two patients with previous ADA-mediated HR (anaphylaxis) to rituximab and tocilizumab. The in vivo and in vitro assays of humoral and cellular response to drugs were carried out in a longitudinal manner throughout the DD cycles. We observed a progressive decrease of the pre-procedure ADA titer with negativization during the DD cycles in both patients. The monitoring of the drug-specific effector cell response showed the decrease in the BA-induced proliferation, while T cell response to unrelated antigens resulted unmodified along the DD cycles. Lastly, the increase of circulating drug-specific Treg cells mainly producing IL-35 were shown during the DD treatment. This study provides evidence that DD treatment to two BA inhibits humoral and cellular anti-drug response by increasing regulatory T cells and cytokines in an antigen-restricted manner. These modifications could contribute to the safety of the procedure.
Collapse
Affiliation(s)
- Alessandra Vultaggio
- Immunoallergology Unit, Department of Medicine and Geriatrics, Careggi University Hospital, Florence, Italy
| | - Francesca Nencini
- Immunoallergology Unit, Department of Medicine and Geriatrics, Careggi University Hospital, Florence, Italy
| | - Susanna Bormioli
- Centre for Research, Transfer and High Education DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Elena Silvestri
- Interdisciplinary Internal Medicine Unit, Neuroskeletal Department and Sense Organs, Careggi University Hospital, Florence, Italy
| | - Laura Dies
- Centre for Research, Transfer and High Education DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Emanuele Vivarelli
- Immunoallergology Unit, Department of Medicine and Geriatrics, Careggi University Hospital, Florence, Italy
| | - Enrico Maggi
- Translational Immunology Unit, Immunology Area, Pediatric Hospital Bambino Gesù, I.R.C.C.S., Rome, Italy.
| | - Andrea Matucci
- Immunoallergology Unit, Department of Medicine and Geriatrics, Careggi University Hospital, Florence, Italy
| |
Collapse
|
2
|
Grieco T, Dies L, Sernicola A, Chello C, Gagliostro N, Carnicelli G, Paolino G. Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment. Immunotherapy 2020; 12:1173-1181. [PMID: 32892673 DOI: 10.2217/imt-2020-0088] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Background: Omalizumab is not considered a disease-modifying drug and, accordingly, a large proportion of patients experience a relapse following withdrawal from treatment. Patients & methods: A total of 42 patients who underwent at least one cycle of treatment with omalizumab were enrolled. Two groups of relapsed and not-relapsed subjects were compared. Then, patients were divided into subgroups. Results: Female patients relapse more frequently than male subjects. Patients who relapsed complained a long duration of disease, while patients who did not relapse had short a history of disease. Very early responders are thought to have a high recurrence rate. Basal IgE levels were increased in early responders and cholesterol levels were high in very early responders, who relapse following withdrawal from omalizumab. High D-dimer levels were observed in late responders. Conclusion: The identification of clinical and serological predictors will play a pivotal role in the future management of patients treated with omalizumab.
Collapse
Affiliation(s)
- Teresa Grieco
- Dermatologic Clinic, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy
| | - Laura Dies
- Dermatologic Clinic, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy
| | - Alvise Sernicola
- Dermatologic Clinic, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy
| | - Camilla Chello
- Dermatologic Clinic, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy
| | - Nazareno Gagliostro
- Dermatologic Clinic, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy
| | - Giorgia Carnicelli
- Dermatologic Clinic, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy
| | - Giovanni Paolino
- Dermatologic Clinic, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy
| |
Collapse
|
3
|
Vultaggio A, Nencini F, Bormioli S, Dies L, Vivarelli E, Maggi E, Matucci A. Desensitization modulates humoral and cellular immune response to infliximab in a patient with an immediate hypersensitivity reaction. J Allergy Clin Immunol Pract 2020; 8:1764-1767.e1. [PMID: 31945487 DOI: 10.1016/j.jaip.2019.12.040] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 12/20/2019] [Accepted: 12/20/2019] [Indexed: 10/25/2022]
Affiliation(s)
- Alessandra Vultaggio
- Immunoallergology Unit, Department of Medicine and Geriatrics, Careggi University Hospital, Florence, Italy
| | - Francesca Nencini
- Immunoallergology Unit, Department of Medicine and Geriatrics, Careggi University Hospital, Florence, Italy
| | - Susanna Bormioli
- Immunoallergology Unit, Department of Medicine and Geriatrics, Careggi University Hospital, Florence, Italy
| | - Laura Dies
- Immunoallergology Unit, Department of Medicine and Geriatrics, Careggi University Hospital, Florence, Italy
| | - Emanuele Vivarelli
- Immunoallergology Unit, Department of Medicine and Geriatrics, Careggi University Hospital, Florence, Italy
| | - Enrico Maggi
- Translational Immunology Unit, Immunology Area, Pediatric Hospital Bambino Gesù, I.R.C.C.S., Rome, Italy.
| | - Andrea Matucci
- Immunoallergology Unit, Department of Medicine and Geriatrics, Careggi University Hospital, Florence, Italy
| |
Collapse
|
4
|
Vultaggio A, Nencini F, Bormioli S, Vivarelli E, Dies L, Rossi O, Parronchi P, Maggi E, Matucci A. Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis. Allergy Asthma Immunol Res 2020; 12:885-893. [PMID: 32638567 PMCID: PMC7346991 DOI: 10.4168/aair.2020.12.5.885] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 03/19/2020] [Accepted: 04/02/2020] [Indexed: 01/21/2023]
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by multisystemic manifestations including asthma. Mepolizumab (300 mg/4 weeks) has recently been approved for EGPA. However, real-life data are scarce and report experiences with high doses of mepolizumab intravenously administered (750 mg/4 weeks). The aim of our study was to investigate in a real-life setting whether mepolizumab in EGPA patients at low doses would enable us 1) to control asthma symptoms, 2) to obtain oral corticosteroids (OCS) and/or immunosuppressors tapering and 3) to maintain clinical remission and avoid disease relapses. Mepolizumab (100 mg/4 weeks) was subcutaneously administered for 12 months in 18 EGPA patients with uncontrolled severe asthma. Symptoms, annual asthma exacerbation rates, OCS-sparing effects, lung function and eosinophil activation markers were monitored. The proportion of patients with clinical remission or relapse was also evaluated in month 12. A significant decrease in the annual rate of asthma exacerbations in association with significant changes in asthma control were observed. Specifically, 66.6% of the patients experienced no exacerbations during the mepolizumab treatment. Most patients (77.7%) were able to reduce the daily OCS dose by at least 50%. Four patients also stopped cyclosporine A during the study period. No EGPA relapse was observed and a large majority of the patients achieved clinical remission (94.3%). Clinical benefits were paralleled by reduction in blood eosinophils and serum levels of eosinophil activation markers. Low-dose mepolizumab showed clinically relevant benefits in exacerbation rates, asthma symptoms, OCS and immunosuppressive use in EGPA patients. These effects occurred without any EGPA relapse for extrapulmonary manifestations.
Collapse
Affiliation(s)
| | - Francesca Nencini
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy
| | - Susanna Bormioli
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy
| | | | - Laura Dies
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy
| | - Oliviero Rossi
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy
| | - Paola Parronchi
- Department of Clinical and Experimental Medicine, Unit of Internal Medicine, University of Florence, Florence, Italy
| | - Enrico Maggi
- Translational Immunology Unit, Immunology Area, Pediatric Hospital Bambino Gesù, IRCCS, Rome, Italy.
| | - Andrea Matucci
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy
| |
Collapse
|
5
|
Dies L, Sernicola A, Magri F, Chello C, Paolino G, Carnicelli G, Faina V, Nencini F, Grieco T. A severe adverse reaction to omalizumab therapy in chronic spontaneous urticaria. Dermatol Ther 2019; 33:e13204. [DOI: 10.1111/dth.13204] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2019] [Accepted: 12/18/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Laura Dies
- Department of DermatologyUniversity of Rome “Sapienza” Rome Italy
| | - Alvise Sernicola
- Department of DermatologyUniversity of Rome “Sapienza” Rome Italy
| | - Francesca Magri
- Department of DermatologyUniversity of Rome “Sapienza” Rome Italy
| | - Camilla Chello
- Department of DermatologyUniversity of Rome “Sapienza” Rome Italy
| | - Giovanni Paolino
- Department of DermatologyUniversity of Rome “Sapienza” Rome Italy
| | | | - Valentina Faina
- Department of DermatologyUniversity of Rome “Sapienza” Rome Italy
| | - Francesca Nencini
- Immunoallergology Unit, Department of BiomedicineAzienda Ospedaliero‐Universitaria Careggi Florence Italy
| | - Teresa Grieco
- Department of DermatologyUniversity of Rome “Sapienza” Rome Italy
| |
Collapse
|
6
|
Pratesi S, Nencini F, Grosso F, Dies L, Bormioli S, Cammelli D, Maggi E, Matucci A, Vultaggio A. T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis. Front Immunol 2019; 9:3113. [PMID: 30687319 PMCID: PMC6336713 DOI: 10.3389/fimmu.2018.03113] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Accepted: 12/17/2018] [Indexed: 11/17/2022] Open
Abstract
This study aimed to evaluate the proportion of infliximab (IFX)-exposed patients exhibiting cellular response to the drug in a longitudinal way and to establish whether it is predictive for anti-drug antibodies (ADA) development. Seventeen patients suffering from immuno-mediated disorders were enrolled. Blood was sampled at baseline and before each of the first eight infusions of IFX. The proliferation of PBMCs to 15-mer peptides covering VH/VL frames of IFX was assessed as well as transcription factors and cytokines mRNA expression of memory T cells in IFX-stimulated PBMCs. The number of peptides recognized by T cells after four infusions was higher than those recognized by the same patients before treatment. IFX-stimulated PBMCs from more than 90% of patients were able to express the main regulators and adaptive cytokines of memory T cells. While IFN-γ mRNAs increased after the first infusion and declined during the subsequent ones, IL-10 mRNA was upregulated throughout the treatment. IL-10 was functionally active because its neutralization improved IFN-γ and IL-13 mRNA expression in vitro. The IL-10/IFN-γ ratio was shown to be lower in patients who developed ADAs solely at the early infusions. IL-10 production consistently preceded or paralleled the IFN-γ onset in ADA– patients, while it was not produced or followed IFN-γ onset in ADA+ patients. In conclusion, this study provides evidence that the majority of exposed patients undergo a cellular response to IFX with the upregulation of IL-10. The development of ADA is associated with the early impairment of IL-10 and low levels of the IL-10/IFN-γ ratio.
Collapse
Affiliation(s)
- Sara Pratesi
- Centre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Francesca Nencini
- Centre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Francesca Grosso
- Centre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Laura Dies
- Centre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Susanna Bormioli
- Centre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Daniele Cammelli
- Immunoallergology Unit, Careggi University-Hospital, Florence, Italy
| | - Enrico Maggi
- Centre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.,Immunology Research Area, IRCSS Bambino Gesù Pediatric Hospital, Rome, Italy
| | - Andrea Matucci
- Immunoallergology Unit, Careggi University-Hospital, Florence, Italy
| | | | | |
Collapse
|
7
|
Matucci A, Liotta F, Vivarelli E, Dies L, Annunziato F, Piccinni MP, Nencini F, Pratesi S, Maggi E, Vultaggio A. Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome. Front Immunol 2018; 9:1198. [PMID: 29896203 PMCID: PMC5986952 DOI: 10.3389/fimmu.2018.01198] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 05/14/2018] [Indexed: 11/21/2022] Open
Abstract
Gleich’s syndrome (GS) is characterized by recurrent episodes of angioedema, increase in body weight, fever, hypereosinophilia, and elevated serum IgM. The exact etiology remains unclear. Currently, the only treatment strategy is the administration of high dose of steroids during the acute phases. We report the case of a 37-year-old man suffering from GS with recurrent episodes of angioedema, fever, hypereosinophilia [6,000/mm3 (45%)], and high eosinophil cationic protein (ECP) (>200 μg/l), treated with oral steroids during the acute phase (prednisone 50–75 mg/day), the dose of maintenance being 25 mg/day. No monoclonal components were identified, and genetic tests exclude mutations including Bcr/Abl, JAK2 V617F, c-KIT D816V, and FIP1L1-PDGFRA. Using Luminex technology, we observed higher serum levels of interleukin (IL)-5, CCL2, and CCL11 during the acute exacerbations in comparison with the clinical remission phases though CCL11 did not achieve statistical significance. The flow-cytometric analysis identified a CD3+ CD8− lymphocyte population with high frequency of IL-4-, IL-5-, and IL-13-producing cells. No clinical benefit was observed after therapeutic strategies with imatinib, interferon-α, cyclosporine-A, and azathioprine. Due to high IL-5 serum levels, an intravenous treatment with anti-IL-5 monoclonal antibody mepolizumab (750 mg every 4 weeks) was started. A reduction in the rate of exacerbation phases/year (10 ± 3 vs 2 ± 1; p < 0.005), in the eosinophils count both in percentage (28.8 ± 12.8 vs 9.8 ± 3.9; p < 0.001) and absolute value (2,737 ± 1,946 vs 782 ± 333; p < 0.001) were observed as well as the ECP serum levels (132.7 ± 62.7 vs 21 ± 14.2 μg/l; p < 0.05). The daily dose of prednisone was significantly reduced (25 vs 7.5 mg). Any adverse effects were recorded. To the best of our knowledge, this case is the first report of the disease successfully treated with mepolizumab, and it could represent a novel therapeutic strategy in GS.
Collapse
Affiliation(s)
- Andrea Matucci
- Department of Biomedicine, Immunoallergology Unit, AOU Careggi, Florence, Italy
| | - Francesco Liotta
- Center for Research, Transfer and High Education DENOTHE, University of Florence, Florence, Italy
| | - Emanuele Vivarelli
- Center for Research, Transfer and High Education DENOTHE, University of Florence, Florence, Italy
| | - Laura Dies
- Center for Research, Transfer and High Education DENOTHE, University of Florence, Florence, Italy
| | - Francesco Annunziato
- Center for Research, Transfer and High Education DENOTHE, University of Florence, Florence, Italy
| | | | - Francesca Nencini
- Center for Research, Transfer and High Education DENOTHE, University of Florence, Florence, Italy
| | - Sara Pratesi
- Center for Research, Transfer and High Education DENOTHE, University of Florence, Florence, Italy
| | - Enrico Maggi
- Center for Research, Transfer and High Education DENOTHE, University of Florence, Florence, Italy
| | | |
Collapse
|
8
|
Dies L, Restagno F, Weil R, Léger L, Poulard C. Role of adhesion between asperities in the formation of elastic solid/solid contacts. Eur Phys J E Soft Matter 2015; 38:130. [PMID: 26687055 DOI: 10.1140/epje/i2015-15130-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Accepted: 11/20/2015] [Indexed: 06/05/2023]
Abstract
We investigated the formation of a contact between a smooth sphere of elastomer and a micro-patterned elastomer substrate. We focussed our attention on the transition between a contact only established at the top of the pillars, and a mixed contact with a central zone of full contact surrounded by a top contact corona, which was observed when the normal load was increased. The full contact zone always nucleated with a finite radius, and the transition appears to be a first-order transition, with a hysteresis due to the creation of an adhesive zone between the pillars. We propose to include the effect of the new inter-pillar adhesion to produce a realistic treatment of the mechanics of these complex contacts. This new approach quantitatively accounts for the evolution of the observed jump in the radius of the full contact with the geometrical parameters of the pattern.
Collapse
Affiliation(s)
- L Dies
- Laboratoire de Physique des Solides, CNRS, Univ. Paris Sud, Université Paris-Saclay, 91405, Orsay Cedex, France
| | - F Restagno
- Laboratoire de Physique des Solides, CNRS, Univ. Paris Sud, Université Paris-Saclay, 91405, Orsay Cedex, France
| | - R Weil
- Laboratoire de Physique des Solides, CNRS, Univ. Paris Sud, Université Paris-Saclay, 91405, Orsay Cedex, France
| | - L Léger
- Laboratoire de Physique des Solides, CNRS, Univ. Paris Sud, Université Paris-Saclay, 91405, Orsay Cedex, France
| | - C Poulard
- Laboratoire de Physique des Solides, CNRS, Univ. Paris Sud, Université Paris-Saclay, 91405, Orsay Cedex, France.
| |
Collapse
|
9
|
Grieco T, Faina V, Dies L, Milana M, Silvestri E, Calvieri S. LATEX sensitization in elderly: allergological study and diagnostic protocol. Immun Ageing 2014; 11:7. [PMID: 24822075 PMCID: PMC4017681 DOI: 10.1186/1742-4933-11-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2012] [Accepted: 12/09/2013] [Indexed: 12/05/2022]
Abstract
BACKGROUND The prevalence of latex allergy varies according to the population studied from 3% to 64%. No data exist in the present literature about elderly people because they were not considered among populations at risk. We report a retrospective observational study of 88 elderly patients of our centre of Dermatology and Allergology at Policlinico Umberto I, University of Rome, Sapienza. RESULTS First and second level diagnostic tests showed latex positivity in 11,4% of patients studied for latex allergy in the elderly population. CONCLUSIONS Our study demonstrates a prevalence of elderly-latex sensitization of 11,4%, showing that allergy to latex is a growing disease that can occur at any age. So, we propose these patients as an additional risk category for latex allergy.
Collapse
Affiliation(s)
- Teresa Grieco
- Department of Dermatology, University of Rome “Sapienza”, Viale del Policlinico, 155, 00161 Rome, Italy
| | - Valentina Faina
- Department of Dermatology, University of Rome “Sapienza”, Viale del Policlinico, 155, 00161 Rome, Italy
| | - Laura Dies
- Department of Dermatology, University of Rome “Sapienza”, Viale del Policlinico, 155, 00161 Rome, Italy
| | - Marzio Milana
- Department of Dermatology, University of Rome “Sapienza”, Viale del Policlinico, 155, 00161 Rome, Italy
| | - Emidio Silvestri
- Department of Dermatology, University of Rome “Sapienza”, Viale del Policlinico, 155, 00161 Rome, Italy
| | - Stefano Calvieri
- Department of Dermatology, University of Rome “Sapienza”, Viale del Policlinico, 155, 00161 Rome, Italy
| |
Collapse
|
10
|
Grieco T, Faina V, Dies L, Milana M, Alei L, Silvestri E, Calvieri S. A case of sensitization to alitretinoin. Clin Ter 2013; 164:e207-e209. [PMID: 23868640 DOI: 10.7417/ct.2013.1570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Alitretinoin is a unique retinoid authorised for the treatment of adults with severe chronic hand eczema (CHE) refractory to potent topical steroids. The most common adverse events (AEs) were typical class effects of oral retinoids including headache, flushing and skin disorders. To our knowledge, there are no cases of sensitization to alitretinoin reported in literature. We present a case of sensitization to alitretinoin.
Collapse
Affiliation(s)
- T Grieco
- Department of Dermatology, Sapienza University of Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|
11
|
Grieco T, Faina V, Milana M, Dies L, Bianchini D, Calvieri S. Allergic diseases and climate changes: our experience and an update. Clin Ter 2013; 164:e17-e21. [PMID: 23455746 DOI: 10.7417/ct.2013.1515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
AIMS Recent research has shown that there are many effects of climate change on aeroallergens and thus allergic diseases in humans. It is not easy to evaluate the impact of climate change and air pollution on the prevalence of allergic diseases. The present study is devoted to decipher the possible relationships between climatic changes and allergic diseases, and in particular with atopic dermatitis (AD). MATERIALS AND METHODS To evaluate the aeroallergens effects on AD, we submitted to an allergological study protocol 59 children patients with AD to study the interaction between aeroallergens-atopy patch test (APT) and skin prick test (SPT). The same tests were performed on to the same patients after 24 months to assess the time trend. RESULTS We found a high prevalence of house dust mites and grasses pollen APT positivity in AD's and in respiratory patients and we also found an increase in positive results in the same patients after 24 months. However, we observed a variation in the control group, in which in earlier tests all patients had negative results but after 24 months we found some positivity. CONCLUSION We found a correlation between APT and SPT in AD and we observed a concordance between APT results and the atopy score index, underlying the triggering role of these aereoallergens in the atopic patient's skin reactivity.
Collapse
Affiliation(s)
- T Grieco
- Department of Dermatology, University Sapienza, Rome, Italy.
| | | | | | | | | | | |
Collapse
|
12
|
Grieco T, Faina V, Alei L, Dies L, Milana M, Calvieri S. Systemic contact dermatitis (SCD) due to dietary nickel. Clin Ter 2012; 163:e127-e128. [PMID: 22964704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Systemic contact dermatitis (SCD) can be caused by nickel in sensitized subjects. Nickel allergy is commonly characterized by localized reactions ensuring cutaneous exposure to this element. Systemic reactions can occur after dietary nickel ingestion. We report a case of a woman with Systemic Contact Dermatitis due to nickel.
Collapse
Affiliation(s)
- T Grieco
- Department of Dermatology, University Sapienza, Rome, Italy.
| | | | | | | | | | | |
Collapse
|